Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: Perspectives on the treatment of triazole-resistant infection and utility of airway administration

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4146-4153

  Al Nakeeb, Zaid ^a   Sudan, Ajay ^a   Jeans, Adam R ^a   Gregson, Lea ^a   Goodwin, Joanne ^a   Warn, Peter A ^a   Felton, Timothy W ^a   Howard, Susan J ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; GALACTOMANNAN; ITRACONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FUNGAL STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS; LUNG ENDOTHELIUM; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SYSTEMIC THERAPY; WILD TYPE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELLS, CULTURED; DRUG ADMINISTRATION ROUTES; DRUG RESISTANCE, FUNGAL; FLUCYTOSINE; HUMANS; ITRACONAZOLE; LUNG DISEASES, FUNGAL; MANNANS; MICROBIAL SENSITIVITY TESTS; PULMONARY ALVEOLI; TRIAZOLES;

EID: 84864379147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00141-12     Document Type: Article

References (22)

1. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW. 2012. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin. Microbiol. Infect. doi:10.1111/j.1469-0691.2012.03890.x. [Epub ahead of print.]
2. Campoli P, et al. 2011. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 55:5732-5739.
3. Clinical Laboratory Sciences Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. M38-A. CLSI, Wayne, PA.
4. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
5. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195-204.
6. Denning DW, et al. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97:135-144. (Pubitemid 24250673)
7. Glasmacher A, et al. 2003. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 21:4615-4626. (Pubitemid 46594036)
8. Hoeben BJ, et al. 2006. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:1552-1554.
9. Hope WW, et al. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195:455-466. (Pubitemid 46146125)
10. Hope WW, et al. 2010. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1-→3)-β-D-glucan, and the consequences of delayed antifungal therapy. Antimicrob. Agents Chemother. 54:4879-4886.
11. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
12. Howard SJ, et al. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324 -1332.
13. Lestner JM, et al. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441.
14. Lestner JM, et al. 2009. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 49:928 -930.
15. Marks DI, et al. 2011. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br. J. Haematol 155:318 -327.
16. Marr KA, et al. 2004. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527-1533. (Pubitemid 38168674)
17. Nivoix Y, et al. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176 -1184.
18. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
19. Te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. 2005. Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic mu-rine model of invasive aspergillosis. Antimicrob. Agents Chemother. 49:4220-4226. (Pubitemid 41400967)
20. Verweij PE, Te Dorsthorst DT, Janssen WH, Meis JF, Mouton JW. 2008. In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:4483-4485.
21. Wasylnka JA, Moore MM. 2003. Aspergillus fumigatus conidia survive and germinate in acidic organelles of A549 epithelial cells. J. Cell Sci. 116:1579 -1587.
22. Wasylnka JA, Moore MM. 2002. Uptake of Aspergillus fumigatus conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect. Immun. 70:3156-3163. (Pubitemid 34564179)